Business Value: Ligand Corp (LGND)

Ligand Pharmaceuticals (LGND) relies on an extensive patent portfolio of drug delivery systems, which eliminates competition and guarantees payments for years to come. High-margin revenue is driven by contractual royalties from partners, creating a stable cash flow. Efficiency is maintained through a lean staff of experts and flexible management. This price chart shows that the current figure is 7115.05.

Enterprise value combines market capitalization with net debt, determining the actual cost of a full business buyout while accounting for all liabilities and liquidity. For Ligand Pharmaceuticals (LGND), which effectively monetizes intellectual property through royalties, the aggregate market valuation of the business allows for the comparison of stable cash flows against the asset's real price, eliminating the risk of overpaying for the company.